 | • レポートコード：MRC2305B177 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、230ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に743.45百万ドルであった世界の無細胞タンパク質発現市場規模が、2022年には867.53百万ドルに達し、2027年までに年平均16.94％成長して1,901.69百万ドルになると予測しています。当調査資料では、無細胞タンパク質発現の世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析（大腸菌、昆虫細胞、哺乳動物、ウサギ網状赤血球、小麦胚芽）、発現方法別分析（バッチ式発現、連続フロー式発現）、用途別分析（酵素工学、タンパク質標識、タンパク質精製、タンパク質間相互作用）、エンドユーザー別分析（学術・研究機関、バイオテクノロジー企業、受託研究機関、製薬会社）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目をまとめました。なお、当書に掲載されている企業情報には、Bioneer Corporation、Biotechrabbit GmbH、Cambridge Isotope Laboratories, Inc.、CellFree Sciences Co., Ltd.、CortecNet、Creative Biolabs, Inc.、Cube Biotech GmbH、Cusabio Technology LLC、Daicel Arbor Biosciences、GeneCopoeia, Inc.、GeneFrontier Corporationなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の無細胞タンパク質発現市場規模：製品別 - 大腸菌無細胞タンパク質発現システムの市場規模 - 昆虫細胞無細胞タンパク質発現システムの市場規模 - 哺乳動物無細胞タンパク質発現システムの市場規模 - ウサギ網状赤血球無細胞タンパク質発現システムの市場規模 - 小麦胚芽無細胞タンパク質発現システムの市場規模 ・世界の無細胞タンパク質発現市場規模：発現方法別 - バッチ式発現の市場規模 - 連続フロー式発現の市場規模 ・世界の無細胞タンパク質発現市場規模：用途別 - 酵素工学における市場規模 - タンパク質標識における市場規模 - タンパク質精製における市場規模 - タンパク質間相互作用における市場規模 ・世界の無細胞タンパク質発現市場規模：エンドユーザー別 - 学術・研究機関における市場規模 - バイオテクノロジー企業における市場規模 - 受託研究機関における市場規模 - 製薬会社における市場規模 ・世界の無細胞タンパク質発現市場規模：地域別 - 南北アメリカの無細胞タンパク質発現市場規模 アメリカの無細胞タンパク質発現市場規模 カナダの無細胞タンパク質発現市場規模 ブラジルの無細胞タンパク質発現市場規模 ... - アジア太平洋の無細胞タンパク質発現市場規模 日本の無細胞タンパク質発現市場規模 中国の無細胞タンパク質発現市場規模 インドの無細胞タンパク質発現市場規模 韓国の無細胞タンパク質発現市場規模 台湾の無細胞タンパク質発現市場規模 ... - ヨーロッパ/中東/アフリカの無細胞タンパク質発現市場規模 イギリスの無細胞タンパク質発現市場規模 ドイツの無細胞タンパク質発現市場規模 フランスの無細胞タンパク質発現市場規模 ロシアの無細胞タンパク質発現市場規模 ... - その他地域の無細胞タンパク質発現市場規模 ・競争状況 ・企業情報 |
The Global Cell Free Protein Expression Market size was estimated at USD 743.45 million in 2021 and expected to reach USD 867.53 million in 2022, and is projected to grow at a CAGR 16.94% to reach USD 1,901.69 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cell Free Protein Expression to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across E.coli Cell-free Protein Expression Systems, Insect Cells Cell-free Protein Expression Systems, Mammalian Cell-free Protein Expression Systems, Rabbit Reticulocytes Cell-free Protein Expression Systems, and Wheat Germ Cell-free Protein Expression Systems.
Based on Expression Mode, the market was studied across Batch Expression and Continuous Flow Expression.
Based on Application, the market was studied across Enzyme Engineering, Protein Labeling, Protein Purification, and Protein-Protein Interaction.
Based on End user, the market was studied across Academic and Research Institutes, Biotechnological Companies, Contract Research Organizations, and Pharmaceutical Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cell Free Protein Expression market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cell Free Protein Expression Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Free Protein Expression Market, including Bioneer Corporation, Biotechrabbit GmbH, Cambridge Isotope Laboratories, Inc., CellFree Sciences Co., Ltd., CortecNet, Creative Biolabs, Inc., Cube Biotech GmbH, Cusabio Technology LLC, Daicel Arbor Biosciences, GeneCopoeia, Inc., GeneFrontier Corporation, Jena Bioscience GmbH, LenioBio GmbH, Merck KGaA, New England Biolabs, Inc., Profacgen, Promega Corporation, QIAGEN GmbH, Takara Bio Company, and Thermo Fisher Scientific, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cell Free Protein Expression Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Free Protein Expression Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Free Protein Expression Market?
4. What is the competitive strategic window for opportunities in the Global Cell Free Protein Expression Market?
5. What are the technology trends and regulatory frameworks in the Global Cell Free Protein Expression Market?
6. What is the market share of the leading vendors in the Global Cell Free Protein Expression Market?
7. What modes and strategic moves are considered suitable for entering the Global Cell Free Protein Expression Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rapid prevalence of cancer and infectious disease
5.1.1.2. Growing applications in molecular biologics and applied science
5.1.1.3. Rising inclination toward the personalized medicines
5.1.2. Restraints
5.1.2.1. Lack of stability and flexibility of membrane proteins
5.1.3. Opportunities
5.1.3.1. Significant advancements in rapid cell-free protein expression systems
5.1.3.2. Ongoing research and development in proteomics and genomics
5.1.4. Challenges
5.1.4.1. Issues pertaining to low yield and expensive method
5.2. Cumulative Impact of COVID-19
6. Cell Free Protein Expression Market, by Product
6.1. Introduction
6.2. E.coli Cell-free Protein Expression Systems
6.3. Insect Cells Cell-free Protein Expression Systems
6.4. Mammalian Cell-free Protein Expression Systems
6.5. Rabbit Reticulocytes Cell-free Protein Expression Systems
6.6. Wheat Germ Cell-free Protein Expression Systems
7. Cell Free Protein Expression Market, by Expression Mode
7.1. Introduction
7.2. Batch Expression
7.3. Continuous Flow Expression
8. Cell Free Protein Expression Market, by Application
8.1. Introduction
8.2. Enzyme Engineering
8.3. Protein Labeling
8.4. Protein Purification
8.5. Protein-Protein Interaction
9. Cell Free Protein Expression Market, by End user
9.1. Introduction
9.2. Academic and Research Institutes
9.3. Biotechnological Companies
9.4. Contract Research Organizations
9.5. Pharmaceutical Companies
10. Americas Cell Free Protein Expression Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cell Free Protein Expression Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cell Free Protein Expression Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Bioneer Corporation
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Biotechrabbit GmbH
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Cambridge Isotope Laboratories, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. CellFree Sciences Co., Ltd.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. CortecNet
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Creative Biolabs, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Cube Biotech GmbH
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Cusabio Technology LLC
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Daicel Arbor Biosciences
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. GeneCopoeia, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. GeneFrontier Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Jena Bioscience GmbH
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. LenioBio GmbH
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Merck KGaA
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. New England Biolabs, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Profacgen
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Promega Corporation
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. QIAGEN GmbH
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Takara Bio Company
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Thermo Fisher Scientific, Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing